neoX: Beijing neoX Biotech Closes $30 Million A Round for AI Drug Discovery

Beijing neoX Biotech completed a $30 million Series A Financing for its AI drug discovery platform. The company combines AI and biophysics to discover and develop macromolecular drugs and multi-specific drugs, especially immunoncology therapies, with a particular interest in protein-protein interactions. The A round was co-led by Sky9 Capital and 5Y Capital. Bertelsmann Asia, Vertex Ventures and existing investors Vision Plus Capital and Sequoia Capital China also participated. More details....Share this with colleagues: